Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Dreamy Small-Cap Stocks
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Hedge Your Portfolio with the Equity Bear ETF
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 6.67% |
| STEIN MART I | SMRT | 5.38% |
| ALLIANCE FIB | AFOP | 5.21% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Kensey Nash Corporation ( ) has entered into a manufacturing agreement with London-based medical devices maker Orteq Sports Medicine. The deal includes a minority equity investment in Orteq by Kensey.
Orteq is a global leader in the field of biodegradable polymer technology. The company has developed Actifit for the treatment of meniscal tears, the most common injury of the knees afflicting roughly 1.5 million people annually across the globe. Sports injuries (such as sudden twist of the knee) are the most common cause of meniscal tears.
Actifit, a biocompatible polymer meniscal scaffold, has been designed to offer sports medicine surgeons a novel therapy option for treating irreparable partial meniscal tears. The product is currently marketed throughout Europe and Orteq expects to secure approval of the Food and Drug Administration (“FDA”) to commence U.S. clinical trials in 2011. Actifit is expected to address a target market in excess of $1 billion.
The FDA clearance the U.S. trial will result in an additional $1 million investment in Orteq by Kensey Nash, which will take the total investment to roughly $5 million. This will correspond to approximately 10% stake in Orteq. The deal also provides Kensey Nash with the exclusive worldwide manufacturing rights and entitles it to receive future royalty payments. Other terms are not divulged by the companies.
Pennsylvania-based Kensey Nash is a medical devices company which provides resorbable biomaterials used in a wide variety of medical procedures and endovascular devices. The company’s products are used in cardiovascular, sports medicine, spine, extremities and endovascular markets.
Kensey Nash is currently the exclusive supplier of collagen plugs (one of the key components of the Angio-Seal vascular closure device) to St. Jude Medical ( STJ - Analyst Report ) . The company books a 6% royalty on Angio-Seal net sales by St. Jude.
Kensey Nash reported tepid first-quarter fiscal 2011 results with revenues and net income declining 14% and 21% year over year, respectively. Sports medicine products sales plummeted 26% year over year due to fluctuation in ordering patterns.
The company has pruned its revenue and earnings guidance for fiscal 2011 citing the unfavorable impact of a soft economy on its core businesses. Nevertheless, Kensey Nash expects sales from its sports medicine products to rebound in second-half fiscal 2011.
Read the full Analyst Report on STJ